Montreal, QC – A monumental $49.2 million research cardiovascular disease research program called ARTERIA has been launched in Quebec. The program is aimed at developing ground-breaking treatments for cardiovascular disease.
“Once again, the Montreal Heart Institute and its team of dedicated physicians, researchers and professionals have established themselves as world leaders in the fight against heart disease. This program will have tangible positive effects on patients living with or at risk of developing cardiovascular disease,” said Dr. Jean-Claude Tardif, director of the MHI Research Centre who will be leading the project.
This project has received $49.2 million in funding, with $31M coming from private investments linked to the biopharmaceutical sector and $18.2M from Quebec’s provincial government. Partners in the project include Hoffmann-La Roche, Servier Canada and MedImmune (a subsidiary of AstraZeneca). Other partners include Valeant Canada, Pharmascience, Thrasos Therapeutics, Pfizer Canada, Spartan Bioscience, and the Montreal Heart Institute Foundation.
“We are very proud at the Montreal Heart Institute Research Centre to have succeeded in attracting to this research program such key stakeholders as the Quebec government, Université de Montréal, and the world’s most innovative pharmaceutical companies, so that our patients may benefit from the fruits of this important research,” added Dr. Tardif. He added that ARTERIA will also lead to the creation of 150 new direct, high-skilled jobs.